Plaque Psoriasis

Otezla is now available in the U.S. for the treatment of moderate to severe plaque psoriasis in children and adolescents aged 6 years and older, Amgen announced in a press release.

Artax Biopharma has recruited all 30 patients to a phase 2a clinical trial of AX-158, its investigative Nck modulator for autoimmune diseases, the company announced in a press release.

With Kim Kardashian speaking out about her son’s experience with vitiligo, Healio Dermatology sat with an expert to discuss the condition in the adult and pediatric populations.

The European Commission has granted marketing authorization for two devices that administer Bimzelx for the treatment of multiple inflammatory diseases, UCB announced in a press release.

Arcutis has submitted a supplemental new drug application for Zoryve foam 0.3% for the treatment of scalp and body psoriasis in adults and adolescents aged 12 years and older, according to a company press release.

Patients with psoriasis treated with higher doses of oral zasocitinib experienced greater improvement than those treated with placebo, according to a phase 2b study.

Ilumetri effectively restored the level of well-being of patients with moderate to severe plaque psoriasis to those of the general population, according to interim results released by Almirall.

Vtama cream 1% has been approved in Japan for the treatment of adults with psoriasis as well as patients aged 12 years and older with atopic dermatitis, Dermavant Sciences announced in a press release.

A new antibody injection for the treatment of moderate to severe plaque psoriasis met all primary and key secondary endpoints in a phase 3 Chinese study, Innovent Biologics announced in a release.